Early access program offers experimental spinal cord injury drug
NCT ID NCT04278235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program gives eligible people with acute spinal cord injury early access to the investigational drug elezanumab before it is officially approved. A doctor must decide if the potential benefit outweighs the risks for each patient. The program is only available in certain territories and for those who do not qualify for other treatment options or clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE SPINAL CORD INJURY (SCI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.